CA3012063C - Walnut oligopeptide powder, preparation method and application thereof - Google Patents
Walnut oligopeptide powder, preparation method and application thereof Download PDFInfo
- Publication number
- CA3012063C CA3012063C CA3012063A CA3012063A CA3012063C CA 3012063 C CA3012063 C CA 3012063C CA 3012063 A CA3012063 A CA 3012063A CA 3012063 A CA3012063 A CA 3012063A CA 3012063 C CA3012063 C CA 3012063C
- Authority
- CA
- Canada
- Prior art keywords
- walnut
- preparation
- extraction
- walnut oligopeptide
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000020234 walnut Nutrition 0.000 title claims abstract description 174
- 235000009496 Juglans regia Nutrition 0.000 title claims abstract description 172
- 108010038807 Oligopeptides Proteins 0.000 title claims abstract description 123
- 102000015636 Oligopeptides Human genes 0.000 title claims abstract description 123
- 239000000843 powder Substances 0.000 title claims abstract description 77
- 238000002360 preparation method Methods 0.000 title claims abstract description 69
- 240000007049 Juglans regia Species 0.000 title description 3
- 241000758789 Juglans Species 0.000 claims abstract description 169
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 50
- 238000000034 method Methods 0.000 claims abstract description 45
- 238000000605 extraction Methods 0.000 claims abstract description 40
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 31
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 31
- 239000012528 membrane Substances 0.000 claims abstract description 19
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 12
- 238000001471 micro-filtration Methods 0.000 claims abstract description 8
- 238000001694 spray drying Methods 0.000 claims abstract description 5
- 238000000746 purification Methods 0.000 claims abstract 2
- 230000000694 effects Effects 0.000 claims description 80
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 40
- 239000003814 drug Substances 0.000 claims description 36
- 239000000203 mixture Substances 0.000 claims description 34
- 102000004190 Enzymes Human genes 0.000 claims description 28
- 108090000790 Enzymes Proteins 0.000 claims description 28
- 229940088598 enzyme Drugs 0.000 claims description 28
- 239000000706 filtrate Substances 0.000 claims description 28
- 239000004365 Protease Substances 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 18
- 235000013305 food Nutrition 0.000 claims description 17
- 108090000145 Bacillolysin Proteins 0.000 claims description 15
- 108091005507 Neutral proteases Proteins 0.000 claims description 15
- 102000035092 Neutral proteases Human genes 0.000 claims description 15
- 239000002537 cosmetic Substances 0.000 claims description 15
- 235000015872 dietary supplement Nutrition 0.000 claims description 14
- 238000009826 distribution Methods 0.000 claims description 14
- 239000006228 supernatant Substances 0.000 claims description 13
- 108090000526 Papain Proteins 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 235000019834 papain Nutrition 0.000 claims description 12
- 229940055729 papain Drugs 0.000 claims description 12
- 230000002255 enzymatic effect Effects 0.000 claims description 11
- 239000003531 protein hydrolysate Substances 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 9
- 239000012460 protein solution Substances 0.000 claims description 8
- 238000003825 pressing Methods 0.000 claims description 7
- 210000004556 brain Anatomy 0.000 claims description 6
- 238000005238 degreasing Methods 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 238000009835 boiling Methods 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 108091005658 Basic proteases Proteins 0.000 claims description 4
- 108010004032 Bromelains Proteins 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 235000019835 bromelain Nutrition 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 4
- 239000011148 porous material Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 102000057297 Pepsin A Human genes 0.000 claims description 3
- 108090000284 Pepsin A Proteins 0.000 claims description 3
- 102000004142 Trypsin Human genes 0.000 claims description 3
- 108090000631 Trypsin Proteins 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- 229940111202 pepsin Drugs 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000012588 trypsin Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000007919 dispersible tablet Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 claims description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims description 2
- 239000007941 film coated tablet Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 229940100688 oral solution Drugs 0.000 claims description 2
- 229940100692 oral suspension Drugs 0.000 claims description 2
- 239000012466 permeate Substances 0.000 claims description 2
- 238000007781 pre-processing Methods 0.000 claims description 2
- 239000012465 retentate Substances 0.000 claims description 2
- 239000008298 dragée Substances 0.000 claims 1
- 239000002662 enteric coated tablet Substances 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 239000007940 sugar coated tablet Substances 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 abstract description 15
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 9
- 230000001681 protective effect Effects 0.000 abstract description 4
- 230000003078 antioxidant effect Effects 0.000 abstract description 3
- 230000006866 deterioration Effects 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 241000252212 Danio rerio Species 0.000 description 47
- 210000004027 cell Anatomy 0.000 description 44
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
- 241001098657 Pterois Species 0.000 description 31
- 235000018102 proteins Nutrition 0.000 description 29
- 210000002540 macrophage Anatomy 0.000 description 26
- 229940079593 drug Drugs 0.000 description 25
- 241000699670 Mus sp. Species 0.000 description 23
- 238000012360 testing method Methods 0.000 description 23
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
- 239000012153 distilled water Substances 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 19
- 230000006872 improvement Effects 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 239000000047 product Substances 0.000 description 15
- 239000012085 test solution Substances 0.000 description 15
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 14
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 14
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 14
- 238000002835 absorbance Methods 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 12
- 235000019441 ethanol Nutrition 0.000 description 12
- 238000011534 incubation Methods 0.000 description 12
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 12
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 11
- 230000004071 biological effect Effects 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 210000001161 mammalian embryo Anatomy 0.000 description 11
- 206010057249 Phagocytosis Diseases 0.000 description 10
- 230000008782 phagocytosis Effects 0.000 description 10
- 238000007865 diluting Methods 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 230000009191 jumping Effects 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 238000005303 weighing Methods 0.000 description 9
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 8
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 8
- 239000007853 buffer solution Substances 0.000 description 8
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 229910002092 carbon dioxide Inorganic materials 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 230000006735 deficit Effects 0.000 description 7
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 239000004310 lactic acid Substances 0.000 description 7
- 235000014655 lactic acid Nutrition 0.000 description 7
- 230000033001 locomotion Effects 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 235000010288 sodium nitrite Nutrition 0.000 description 7
- 239000012224 working solution Substances 0.000 description 7
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 6
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 6
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 6
- 229960002646 scopolamine Drugs 0.000 description 6
- 235000010265 sodium sulphite Nutrition 0.000 description 6
- 238000012549 training Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 238000003916 acid precipitation Methods 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000005056 memory consolidation Effects 0.000 description 5
- 230000002000 scavenging effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000009210 therapy by ultrasound Methods 0.000 description 5
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 4
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241000758791 Juglandaceae Species 0.000 description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 4
- 229940093265 berberine Drugs 0.000 description 4
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000004043 dyeing Methods 0.000 description 4
- -1 for example Substances 0.000 description 4
- 230000007760 free radical scavenging Effects 0.000 description 4
- 235000013922 glutamic acid Nutrition 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- 229960003180 glutathione Drugs 0.000 description 4
- 238000011031 large-scale manufacturing process Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000008035 nerve activity Effects 0.000 description 4
- 229960001163 pidotimod Drugs 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 102000013691 Interleukin-17 Human genes 0.000 description 3
- 108050003558 Interleukin-17 Proteins 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229960005261 aspartic acid Drugs 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000004720 fertilization Effects 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 3
- 102000013498 tau Proteins Human genes 0.000 description 3
- 108010026424 tau Proteins Proteins 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 2
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- 229930182844 L-isoleucine Natural products 0.000 description 2
- 239000004395 L-leucine Substances 0.000 description 2
- 235000019454 L-leucine Nutrition 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 229930195722 L-methionine Natural products 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 229930182821 L-proline Natural products 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 210000002308 embryonic cell Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 229960002885 histidine Drugs 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 229960003136 leucine Drugs 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000006386 memory function Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 229940014456 mycophenolate Drugs 0.000 description 2
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- 230000004845 protein aggregation Effects 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000000194 supercritical-fluid extraction Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229960002898 threonine Drugs 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- 229960004295 valine Drugs 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- OCZVHBZNPVABKX-UHFFFAOYSA-N 1,1-diphenyl-2-(2,4,6-trinitrophenyl)hydrazine;ethanol Chemical compound CCO.[O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NN(C=1C=CC=CC=1)C1=CC=CC=C1 OCZVHBZNPVABKX-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 239000004158 L-cystine Substances 0.000 description 1
- 235000019393 L-cystine Nutrition 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000036978 cell physiology Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- XQGPKZUNMMFTAL-UHFFFAOYSA-L dipotassium;hydrogen phosphate;trihydrate Chemical compound O.O.O.[K+].[K+].OP([O-])([O-])=O XQGPKZUNMMFTAL-UHFFFAOYSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- DGLRDKLJZLEJCY-UHFFFAOYSA-L disodium hydrogenphosphate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O DGLRDKLJZLEJCY-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 238000007731 hot pressing Methods 0.000 description 1
- 102000057063 human MAPT Human genes 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229960004499 scopolamine hydrobromide Drugs 0.000 description 1
- WTGQALLALWYDJH-MOUKNHLCSA-N scopolamine hydrobromide (anhydrous) Chemical compound Br.C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 WTGQALLALWYDJH-MOUKNHLCSA-N 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 230000031836 visual learning Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/14—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from leguminous or other vegetable seeds; from press-cake or oil-bearing seeds
- A23J1/148—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from leguminous or other vegetable seeds; from press-cake or oil-bearing seeds by treatment involving enzymes or microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/30—Working-up of proteins for foodstuffs by hydrolysis
- A23J3/32—Working-up of proteins for foodstuffs by hydrolysis using chemical agents
- A23J3/34—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes
- A23J3/346—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/645—Proteins of vegetable origin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/145—Ultrafiltration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/147—Microfiltration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/149—Multistep processes comprising different kinds of membrane processes selected from ultrafiltration or microfiltration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/145—Extraction; Separation; Purification by extraction or solubilisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Water Supply & Treatment (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Birds (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610043952.0A CN105567774B (zh) | 2016-01-22 | 2016-01-22 | 一种核桃低聚肽粉及其制备方法和用途 |
| CN201610043952.0 | 2016-01-22 | ||
| PCT/CN2017/000121 WO2017124921A1 (zh) | 2016-01-22 | 2017-01-18 | 一种核桃低聚肽粉及其制备方法和用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3012063A1 CA3012063A1 (en) | 2017-07-27 |
| CA3012063C true CA3012063C (en) | 2024-03-05 |
Family
ID=55878392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3012063A Active CA3012063C (en) | 2016-01-22 | 2017-01-18 | Walnut oligopeptide powder, preparation method and application thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11072637B2 (ja) |
| EP (1) | EP3406625B1 (ja) |
| JP (1) | JP6828054B2 (ja) |
| KR (1) | KR102320465B1 (ja) |
| CN (2) | CN105567774B (ja) |
| AU (1) | AU2017209066C1 (ja) |
| CA (1) | CA3012063C (ja) |
| MY (1) | MY193780A (ja) |
| WO (1) | WO2017124921A1 (ja) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105567774B (zh) * | 2016-01-22 | 2019-09-10 | 杏辉天力（杭州）药业有限公司 | 一种核桃低聚肽粉及其制备方法和用途 |
| CN105936927B (zh) * | 2016-05-19 | 2020-02-14 | 杏辉天力（杭州）药业有限公司 | 一种核桃低聚肽及其制备工艺和用途 |
| CN105949290B (zh) * | 2016-05-30 | 2019-11-08 | 杏辉天力（杭州）药业有限公司 | 一种鹰嘴豆蛋白粉和低聚肽粉及制备方法和用途 |
| CN107080256A (zh) * | 2017-05-17 | 2017-08-22 | 北京泓九生物科技有限公司 | 一种核桃低聚肽与大枣多糖的复合物及其制备方法 |
| CN107439787B (zh) * | 2017-07-18 | 2021-04-23 | 杏辉天力（杭州）药业有限公司 | 一种具有抗pm 2.5颗粒物功效的核桃低聚肽 |
| CN107440114B (zh) * | 2017-07-18 | 2021-02-05 | 杏辉天力（杭州）药业有限公司 | 一种具有抗pm2.5颗粒物功效的组合物 |
| CN107365821A (zh) * | 2017-09-01 | 2017-11-21 | 杏辉天力（杭州）药业有限公司 | 一种具有美白功效的核桃低聚肽粉 |
| CN107439634A (zh) * | 2017-09-05 | 2017-12-08 | 安徽华健生物科技有限公司 | 一种降脂减肥的脱脂核桃点心的制备方法 |
| CN108796016B (zh) * | 2018-06-21 | 2022-08-05 | 重庆申高生化制药股份有限公司 | 核桃肽及其酶解提取方法 |
| CN109589400B (zh) * | 2018-12-30 | 2022-10-04 | 杏辉天力（杭州）药业有限公司 | 一种具有神经保护功效的组合物 |
| CN109762862B (zh) * | 2019-03-04 | 2023-01-24 | 武汉百理王生物工程有限公司 | 一种高纯度莲子蛋白低聚肽的制备方法 |
| WO2020248947A1 (zh) * | 2019-06-10 | 2020-12-17 | 杏辉天力杭州药业有限公司 | 一种核桃低聚肽粉及其制备方法和用途 |
| CN110915926A (zh) * | 2019-11-22 | 2020-03-27 | 河北绿蕾农林科技有限公司 | 一种复合核桃蛋白粉及其制备方法 |
| KR102212894B1 (ko) * | 2020-05-20 | 2021-02-05 | 주식회사 코씨드바이오팜 | 호두 펩타이드를 유효성분으로 함유하는 모발 볼륨감 강화용 화장료 조성물 |
| CN111777662B (zh) * | 2020-07-27 | 2021-03-30 | 佛山市百分之秀化妆品有限公司 | 一种活性多肽、制备方法和在抗衰老化妆品方面的应用 |
| CN111808905B (zh) * | 2020-07-27 | 2023-02-10 | 吴伟 | 从低温压榨山核桃饼粕中提取核桃低聚肽的方法及其应用 |
| CN111892644B (zh) * | 2020-07-31 | 2022-07-05 | 吉林农业大学 | 一种保护神经细胞氧化应激的改善记忆力活性肽及其制备方法 |
| CN112618406A (zh) * | 2020-12-30 | 2021-04-09 | 杭州娃哈哈科技有限公司 | 一种具有自由基清除作用的苦瓜籽肽粉及其制备方法和应用 |
| CN113100320B (zh) * | 2021-04-12 | 2022-09-27 | 武汉轻工大学 | 一种具有缓解亚健康疲劳功能的核桃低聚肽糖果及其制备方法 |
| CN113481273A (zh) * | 2021-07-19 | 2021-10-08 | 新疆农业科学院农业机械化研究所 | 以低温物理脱脂巴旦杏粕为原料制备巴旦杏低聚肽的方法及其包含巴旦杏低聚肽的口服液 |
| WO2023049479A1 (en) * | 2021-09-24 | 2023-03-30 | Jds Therapeutics, Llc | Compositions and uses of oligo-chromopeptides and methods of making |
| CN113854398A (zh) * | 2021-10-08 | 2021-12-31 | 长春大学 | 一种核桃饼粕为原料制备免消化核桃蛋白质的方法 |
| CN114058665A (zh) * | 2021-12-02 | 2022-02-18 | 浙江宜格企业管理集团有限公司 | 一种复合花肽的制备方法及其在制备化妆品中的应用 |
| CN114606283B (zh) * | 2021-12-17 | 2023-08-15 | 陕西师范大学 | 一种具有良好乳化性能的核桃多肽及其制备方法 |
| CN114246934B (zh) * | 2021-12-17 | 2024-03-15 | 吉林农业大学 | 一种协同增效保护神经的活性物质组合物及其应用 |
| CN114044811B (zh) * | 2022-01-13 | 2022-04-12 | 中食都庆（山东）生物技术有限公司 | 一种核桃肽及其制备方法和应用 |
| CN114213507B (zh) * | 2022-01-13 | 2023-10-13 | 中食都庆（山东）生物技术有限公司 | 一种核桃肽及其制备方法和应用 |
| CN114751957B (zh) * | 2022-03-15 | 2024-02-02 | 吉林农业大学 | 一种高抗氧化可穿透血脑屏障的改善记忆力衍生肽及其应用 |
| CN117778509B (zh) * | 2024-01-04 | 2024-06-07 | 吉林肽谷生物工程有限责任公司 | 核桃肽提取方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050249865A1 (en) * | 2002-08-05 | 2005-11-10 | Xinqi Liu | Process for producing soy protein |
| US7354616B2 (en) * | 2003-11-25 | 2008-04-08 | Solae, Llc | Modified oilseed material with a high gel strength |
| JPWO2005120244A1 (ja) * | 2004-06-07 | 2008-04-03 | 不二製油株式会社 | 大豆蛋白加水分解物の製造法 |
| CN101228918A (zh) * | 2007-01-24 | 2008-07-30 | 西北农林科技大学 | 一种核桃多肽粉的制作方法 |
| CN101280327B (zh) * | 2008-05-26 | 2012-03-21 | 昆明理工大学 | 核桃油和核桃蛋白肽的同步水酶超声提取法 |
| CN102406050B (zh) | 2011-11-17 | 2013-08-07 | 中国农业大学 | 一种核桃小分子多肽及其制备方法 |
| CN103103244B (zh) * | 2013-02-22 | 2014-12-03 | 北京市农林科学院 | 核桃降血压活性肽及其制备方法与应用 |
| CN103109971B (zh) * | 2013-03-04 | 2014-09-10 | 四川省均易润泽食品有限公司 | 制备高精氨酸核桃肽的方法 |
| CN103125735A (zh) * | 2013-03-11 | 2013-06-05 | 武汉工业学院 | 一种核桃多肽的制备方法 |
| CN103497985B (zh) * | 2013-09-06 | 2015-10-28 | 华南理工大学 | 核桃粕抗氧化肽及其制备方法 |
| CN103484518B (zh) * | 2013-09-11 | 2016-03-30 | 邹远东 | 一种核桃蛋白肽及其制备方法和其应用 |
| CN104031968B (zh) * | 2014-06-27 | 2016-10-19 | 广西壮族自治区中国科学院广西植物研究所 | 核桃多肽的应用 |
| CN104293870B (zh) | 2014-09-25 | 2017-11-21 | 汾州裕源土特产品有限公司 | 一种抗氧化核桃多肽保健品的制备方法 |
| CN105002247A (zh) * | 2015-07-30 | 2015-10-28 | 北京天肽生物科技有限公司 | 一种小分子核桃肽及其制备方法 |
| CN105567774B (zh) * | 2016-01-22 | 2019-09-10 | 杏辉天力（杭州）药业有限公司 | 一种核桃低聚肽粉及其制备方法和用途 |
| CN105936927B (zh) * | 2016-05-19 | 2020-02-14 | 杏辉天力（杭州）药业有限公司 | 一种核桃低聚肽及其制备工艺和用途 |
| CN106520872A (zh) * | 2016-10-13 | 2017-03-22 | 杏辉天力（杭州）药业有限公司 | 一种具有抗疲劳功效的核桃低聚多肽 |
-
2016
- 2016-01-22 CN CN201610043952.0A patent/CN105567774B/zh active Active
-
2017
- 2017-01-18 MY MYPI2018702546A patent/MY193780A/en unknown
- 2017-01-18 KR KR1020187023722A patent/KR102320465B1/ko active IP Right Grant
- 2017-01-18 US US16/071,583 patent/US11072637B2/en active Active
- 2017-01-18 CA CA3012063A patent/CA3012063C/en active Active
- 2017-01-18 CN CN201780007467.0A patent/CN109071599A/zh active Pending
- 2017-01-18 EP EP17740952.1A patent/EP3406625B1/en active Active
- 2017-01-18 JP JP2018557173A patent/JP6828054B2/ja active Active
- 2017-01-18 WO PCT/CN2017/000121 patent/WO2017124921A1/zh active Application Filing
- 2017-01-18 AU AU2017209066A patent/AU2017209066C1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017209066C1 (en) | 2021-05-27 |
| JP2019506451A (ja) | 2019-03-07 |
| WO2017124921A1 (zh) | 2017-07-27 |
| CN109071599A (zh) | 2018-12-21 |
| MY193780A (en) | 2022-10-27 |
| AU2017209066B2 (en) | 2020-01-30 |
| CN105567774A (zh) | 2016-05-11 |
| EP3406625A1 (en) | 2018-11-28 |
| AU2017209066A1 (en) | 2018-08-23 |
| KR102320465B1 (ko) | 2021-11-02 |
| WO2017124921A9 (zh) | 2018-08-09 |
| JP6828054B2 (ja) | 2021-02-10 |
| CN105567774B (zh) | 2019-09-10 |
| US11072637B2 (en) | 2021-07-27 |
| EP3406625B1 (en) | 2021-08-25 |
| US20190276504A1 (en) | 2019-09-12 |
| CA3012063A1 (en) | 2017-07-27 |
| KR20180100234A (ko) | 2018-09-07 |
| EP3406625A4 (en) | 2019-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3012063C (en) | Walnut oligopeptide powder, preparation method and application thereof | |
| TWI782283B (zh) | 一種核桃低聚肽粉的用途 | |
| CN111670997B (zh) | 增强免疫复合蛋白肽酶解液的制备方法、增强免疫复合蛋白肽饮品及其制备方法 | |
| JP2019506451A5 (ja) | ウォールナットオリゴペプチド粉、その調製方法と使用 | |
| CN105936927B (zh) | 一种核桃低聚肽及其制备工艺和用途 | |
| CN111019990B (zh) | 一种南瓜籽肽粉及其制备方法和用途 | |
| JP5154964B2 (ja) | ローヤルゼリー分解酵素含有物 | |
| CN107929091A (zh) | 一种高活性胶原蛋白的提取方法及其应用 | |
| KR101226548B1 (ko) | 바실러스 속 ｋｈ-15의 콩 발효물을 유효성분으로 포함하는 당뇨병 예방 및 치료용 조성물 | |
| US20240139281A1 (en) | Use of goji glycopeptide in preparation of drug for preventing and/or treating amyotrophic lateral sclerosis | |
| CN110577976A (zh) | 一种绿豆低聚肽粉及其制备方法 | |
| WO2018021471A1 (ja) | 脳機能改善するための食品組成物 | |
| Ding et al. | Peanut meal extract fermented with Bacillus natto attenuates physiological and behavioural deficits in a D-galactose-induced ageing rat model | |
| EP2087899B1 (en) | Grifola frondosa-derived substance having anti-influenza virus activity and method for producing the same | |
| EP2730586B1 (en) | Protein-polypeptide complex obtained from tissues of hoofed livestock embryos, process for preparing same and pharmaceutical composition | |
| CN115644455B (zh) | 牛脾肽粉在改善肠道功能中的用途 | |
| CN109589400A (zh) | 一种具有神经保护功效的组合物 | |
| CN107446975B (zh) | 一种高纯核桃低聚肽及其工业化制备方法和用途 | |
| KR20090012327A (ko) | 중추 신경계 뉴런의 재생을 자극하는 펩타이드 물질, 이를 기저로 하는 약제학적 조성물 및 이의 적용 방법 | |
| RU2075944C1 (ru) | Способ получения белковой пищевой добавки | |
| CN110106221A (zh) | 海参寡肽及其制备方法与应用 | |
| CN109568261A (zh) | 一种预防和缓解化学性肝损伤的多肽口服液及其制备方法 | |
| CN113412935A (zh) | 一种海参美容保健品及其制备方法 | |
| CN112841406A (zh) | 一种乌鸡的深加工工艺及乌鸡多肽蛋白粉 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200124 |
|
| EEER | Examination request |
Effective date: 20200124 |
|
| EEER | Examination request |
Effective date: 20200124 |
|
| EEER | Examination request |
Effective date: 20200124 |
|
| EEER | Examination request |
Effective date: 20200124 |
|
| EEER | Examination request |
Effective date: 20200124 |
|
| EEER | Examination request |
Effective date: 20200124 |